-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 12, 2021, Corium announced that the US FDA has set the new drug application (NDA) PDUFA target date for its donepezil (donepezil) transdermal patch Adlarity to March 11, 2022 for the treatment of mild/medium/ Patients with dementia caused by severe Alzheimer's disease
According to statistics from the World Health Organization, more than 55 million people worldwide suffer from dementia, and Alzheimer's disease accounts for approximately 60%-70% of these patients
Donepezil is a common cholinesterase inhibitor (cholinesterase inhibitors)
Adlarity is a transdermal preparation of donepezil, made using Corium's proprietary Corplex technology platform
With the slow and stable release of donepezil, the Adlarity transdermal system can regularly deliver the drug through the skin.
Reference materials:
[1] Corium Receives March 11, 2022 PDUFA Date for New Drug Application for Adlarity® Patch (donepezil transdermal system) for Treatment of Patients with Alzheimer's Disease.
(The original text has been deleted)